The FDA has accepted a supplemental Biologics License Application (sBLA) for Botox Cosmetic to treat masseter muscle prominence, advancing AbbVie's effort to expand the toxin's approved indications beyond the current glabellar, forehead, and crow's feet labels.
Regulatory
FDA Accepts sBLA for Botox in Masseter Prominence
AbbVie advances jawline indication; regulatory path clears for new patient population.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |